Clinical Trials Logo

Refractory AML clinical trials

View clinical trials related to Refractory AML.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT05193448 Completed - Relapsed Adult AML Clinical Trials

A Non-interventional Ambispective Real-world Cohort of rEfractory and reLapsed (R/R) FLT3 Mutated Acute MyEloid Leukemia (AML) Patients Treated With Gilteritinib in FrANCE

ELEGANCE
Start date: July 5, 2021
Phase:
Study type: Observational [Patient Registry]

Gilteritinib is available in early access in France through Temporary Authorisation of Use (or ATU program) since March 2019. The ATU program reflects a real-life treatment situation and the related clinical data would help to better understand the benefit/risk profile of gilteritinib and to better document gilteritinib efficacy and safety in patients who received midostaurine in First Line (1L) setting. The main objective is to describe gilteritinib effectiveness in FLT3 (Fms Related Tyrosine Kinase 3) -mutated AML patients in Refractory/Relapsed(R/R) situation treated in the context of early access program to gilteritinib in France through Temporary Authorisation of Use, the so-called ATU program, and the post ATU period from marketing authorisation to launch when reimbursement and price are published.

NCT ID: NCT02675478 Completed - Refractory AML Clinical Trials

Phase 1 Study of Quizartinib

Start date: February 2016
Phase: Phase 1
Study type: Interventional

This is a dose escalation study to evaluate the safety, tolerability, and pharmacokinetics of quizartinib for Japanese acute myeloid leukemia (AML) subjects.